GSK announced it has entered a multi-year strategic collaboration agreement with Helix aiming to drive the development of precision medicines.

The announcement comes on the heels of FDA’s approval of GSK’s Exdensur for adolescents and adults with severe asthma characterized by an eosinophilic phenotype.

"We are looking forward to working with Helix as part of our strategy to integrate genetics and genomics as a core part of our decision making. Bringing Helix into our network of collaborations will greatly enable our work to understand the aetiology of disease, discover, develop and deliver medicines to patients," Robert Scott, vice president of human genetics and genomics of GSK.

What are the details of the collaboration?

The collaboration agreement is expected to provide GSK access to Helix's evolving phenotyped GenoSphere cohorts that span across several disease areas.¹ The four cohorts are comprised of comprehensive Exome+ genomic and rich longitudinal clinical data, and are enhanced with third party medical, pharmacy, and mortality claims.¹

Helix’s GenoSphere cohorts include the following:

• Autoimmune: Comprised of less than 35,000 patients and consists of whole Exome+ sequencing profiles for diverse individuals diagnosed with conditions such as Lupus, Rheumatoid Arthritis, Psoriasis, Multiple Sclerosis, Hashimoto's disease, Chron’s, lab results and procedures, along with linked medical and pharmacy claims data.³
• Cardiovascular, Renal, Metabolic: Includes over 165,000 patients and was created to support target identification and biomarker discovery and or help identify and recruit patients for clinical trials.³
• GLP-1 Receptor Agonists: Consists of whole Exome+ sequencing profiles for upwards of 18,000 patients treated by GLP-1 agonist combined with longitudinal and regularly refreshed EHR data including demographics, clinical diagnoses (T2D, CVD, obesity, kidney diseases, etc), lab results, procedures, and linked medical and pharmacy claims data.³
• MASH/MAFLD: Is comprised of less than 10,000 participants and consists of whole Exome+ sequencing profiles for consented individuals paired with longitudinal clinical data that covers decades including demographics, related diagnoses, major lab results including Fibrosis-4 scores, past procedures and insights, with the ability to link medical and mortality claims data.³

GenoSphere cohorts are designed to accelerate life sciences research across the development cycle, and are powered by Helix Research Network, the largest and fastest growing precision health network in the world.¹ The Helix Research Network was designed to help empower health systems to leverage collective genomic intelligence, advance precision medicine, and enhance patient care.²

"We are excited to establish this foundational collaboration with GSK," said James Lu, M.D., Ph.D., CEO of Helix. "The collaboration demonstrates the unparalleled scale and comprehensive utility of our platform to potentially help transform drug development across major therapeutic areas and further cements Helix's role as a catalyst for the future of precision medicine at a global level."

Sources

1. Helix Announces Multi-Year Strategic Collaboration with GSK to Drive Precision Medicine Development. Helix. January 7, 2026. https://www.prnewswire.com/news-releases/helix-announces-multi-year-strategic-collaboration-with-gsk-to-drive-precision-medicine-development-302654760.html

2. Helix Research Network. Helix. Accessed January 7,2027. https://www.helix.com/what-we-do/helix-research-network

3. Helix GenoSphere. Helix. AccessedJanuary 7, 2027. https://www.helix.com/what-we-do/helix-genosphere